The importance of serum insulin-like growth factor-I level determination in the follow-up of patients with epithelial ovarian cancer

Purpose of investigation: The aim of our study was to assess whether serum levels of serum insulin-like growth factor-I (IGF-I) could be used for the follow-up of the patients with epithelial ovarian cancer and to identify whether it was superior to serum CA 125.

Methods: Our study group consisted of 28 patients diagnosed with epithelial ovarian cancer who had initial high serum CA 125 levels and have received chemotherapy following the operation. Preoperatively and before each chemotherapy administration, serum CA 125 and IGF-I levels were measured.

Results: The mean value of preoperative serum CA 125 was 364.0 +/- 152.9 U/ml. Serum CA 125 levels decreased with chemotherapy (Spearman rs= - 0.641, p=0.000). The mean preoperative serum IGF-I concentration was 58.04 +/- 52.7 ng/ml, and it showed a slight increase with chemotherapy. (Spearman rs=0.3 18, p=0.001). We observed that there was a weak-moderate negative correlation between the two markers, and when chemotherapy was administered serum CA 125 levels which were initially high started to decrease while serum IGF-I levels showed a mild increase (Spearman rs= - 0.350, p=0.000).

Conclusion: The measurement of serum IGF-I does not provide any additional benefit in monitoring the response of the disease to chemotherapy.

Epithelial ovarian cancer; IGF-1; CA 125

[1] Rotwein P.: "Structure, evaluation, expression and regulation ofmsulin-like growth factors I and II". Growth Factors, 1991, 5,3.

[2] Daughaday W. H.: "Growth hormone, insulin-like growth factors, and acromegaly". In: DeGroot L. J., ed. "Endocrinology". 3rd ed Philadelphia, W. B.Saunders, 1995, 303.

[3] Wang H. S., Chard T.: "The role of insulin-like growth factor I and insulin-like growth factor binding protein I in the control of human fetal growth". J. Endocrinol., 1992, 132, 11.

[4] Clemmons D. R.: "Insulin-like growth factor binding proteins: roJes in regulating IGF physiology". J. Dev. Physiol., 1991, 15, 105.

[5] Geisthovel F., Moretti-Rojas I., Roja、F. J., Asch R. H.: "Insulinlike growth factors and thecal-granulosa-cell t.Unction". Hum. Reprod., 1990, 5, 785.

[6] Daughaday W. H., Rotwein P.: "Insulin-like growth factors I and 2. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations". Endocr. Rev., 1989, 10, 68.

[7] Daughaday W. H.,D eul T. F.:'Tumor secretion of growth factors" Endocrinol. Metab. Clin. North Am.. 1991, 20, 539.

[8] Macaulay V. M.: "Insulin like growth factors and cancer". Br. J Cancer, 1992, 65, 311.

[9] Daughaday W. H. : "The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors". Endocrinology, 1990, 127, 1.

[10] Peyrat J.P.,B onneterre J., Beuscart R., Djiane J.,D emaille A.: "Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors". Cancer Res., 1988, 48, 6429.

[11] Yee D., Morales F. R., Hamlton T. C., Von HoffD. D.: "Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer". Cancer Res., 1991, 51, 5107.

[12] Resnicoff M., Ambrose D., Coppola D.. Rubin R.: "Insulin-like growth factor l and its receptor mediated the autucrine proliferation of human ovarian carcinoma cell lines". Lab. Invest., 1993, 69, 756.

[13] Bast R. C., Klug T. L., St. John E.. Jenison E.，Niloff J. M., Lazarus H. et al. "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". The New Eng. J. Med., 1983, 309, 883.

[14] Bast R. C., Klug T. L. , Schaetzl. E. ,L avin P.,N iloff J. M.,Greber T. F. et al.: "Monitoring human ovarian carcinoma with a combination of CA 125, CA 199, and CEA". Am. J. Obstet. Gynecol., 1984, 149., 553.

[15] Be􀆌e T., Oz A.U.,D emirk1ran F.,K aleli S.,A rvas M., Kosebay D.: "What should be the cut-off level of serum CA 125 to evaluate the disease status before second-look laparotomy in epithelial ovarian carcinoma?" Int. J. Gynecol. Cancer, 1997, 7, 42.

[16] Sevelda P., Schemper M., Spona J.: "CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1989, 161, 1213.

[17] Hunter V. J.,D aly L., Helms M., Soper J. T., Berchuck A.,C larkePearson D. L., Bast R. C.: "The prognostic significance of CA 125 half life in patients with ovarian cancer who have received primary chemotherapy at.ter surgical cytoreduction". Am. J. Obstet. Gynecol., 1990, 163, 1164.

[18] Koelbl H., Schnieder K., Neunteufel W., Biegimayer C.: "A comparative study of mucin-like carcinoma associated antigen (MCA), CA 125, CA 199 and CEA in patients with ovarian cancer". Neoplasma, 1989, 36, 473.

[19] Fioretti P., Gadducci A., Ferdeghini M.. Bartolini T., Fontana U., Facchini V.: "Preoperative evaluation of CA 125 and CA 199 serum levels in patients with ovarian masses". Eur. J. Gynaecol. Oncol., 1988, 9, 291.

[20] Gadducci A., Ferdeghini M., Ceccarini T., Prontera C., Facchini V., Bianchi R., Fioretti P.: "A comparative evaluation of the ab山ty of serum CA 125 , CA-199, CA 153, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma". Eur. J. Gynaecol. Oncol., 1990, 11, 127.

[21] Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P. et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998, 280, 719.

[22] Berchuck A., Olt G. J., Everitt L., Soisson A. P. , Bast R. C., Boyer C. M.: "The role of peptide growth factors in epithelial ovarian cancer". Obstet. Gynecol., 1990, 75, 255.

[23] Goustin A. S.. Leof E. B., Shipley G.D., Moses H. L.: "Growth factors and cancer". Cancer Res., 1986, 46, 1015.

[24] Browder T. M.,D unbar C.,N ienhuis A.W.: "Private and pubhc autocrine loops in neoplastic cells". Cancer, 1989, 1, 9.

[25] Sporn M. B., Roberts A. B.: "Autocrine growth factors and cancer". Nature, 1985, 313, 745.

[26] Beck E. P., Russo P., Gliozzo P., Jaeger W., Papa Y., Wildt L. et al.: "ldentification of insulin and insulin-like growth factor-1 (IGF-1) receptors in ovarian cancer tissue". Gynecol. Oneal., 1994, 53, 196.

[27] Froesch E. R., Schmid C., Schwander J., Zapf J.: "Actions of msuJin-like growth factors". Ann. Rev. Physiol., 1985, 47, 443.

[28] Zapf J., Schmid C., Froesch E.R.: "Biological and immunological properties of insulin-like growth factors (IGF ) I and II". Clin. Endocrinol. Metab., 1984, 13, 3.

[29] Chandrasekhar Y., Heiner C., Osuamkpe C., Nagamani M.: "Insulin-like growth factor I and II binding in human myometrium and liomyomas". Am. J. Obstet. Gynecol., 1992, 166, 64.

[30] Chang S. Y., Ho Y. S.: "Immuno-histochemical analysis of insulinlike growth factor-I, insulin-like growth factor-I receptor and insulin-like growth factor II in endometriotic tissue and endometrium" Acta Obstet. Gynecol. Scand., 1997, 76, 112.

[31] Poretsky L., Bhargava G., Levitan E.: "Type-I insulin-like growth factor receptors in human ovarian stroma". Horm. Res., 1990, 33, 22.

[32] Nagamani M., Stuart C.A.: "Specific binding sites for insulin-like growth factor-1 in the ovarian stroma of woman with polycystic ovarian disease and stromal hyperthecosis". Am. J. Obstet. Gynecol., 1990, 163, 1992.

[33] Papa Y., Pezzino Y., Costantino A., Belfiore A., Giuffrida O., Frittitta L. et al.: "Elevated insulin receptor content in human breast cancer". J. Clin. Invest., 1990, 86,1503.

[34] Stewart A. J., Jonson M. D., May F. E., Westley B. R.: "Role of msulin-like growth factors and type I insulin-like growth factor receptor in the estrogen stimulated proliferation of human breast cancer cells". J. Biol. Chem., l 990,265, 21172.

[35] Talavera F., Reynolds R. K., Roberts J. A., Menon K. M.: "Insulinlike growth factor -I receptors in normal and neoplastic human endometrium". Cancer Res., 1990, 50, 3019.

[36] Nagamani M.. Stuart C. A.,D unhardt P.A.,D oherty M. G.: "Specific binding sites for insulin and insulin-like growth factor-I in human endometrial cancer". Am. J. Obstet. Gynecol., 1991, 65, 1865.

[37] Bauknecht T., Kiechle M., Bauer G., Siebers J. W.: "Charactenzation of growth factors in human ovarian carcinomas". Cancer Res., 1986, 46, 2614.

[38] Wilson A. P., Fox H.. Scott I. Y.,L ee H.,D ent M., Golding P. R.； "A comparison of the growth promoting properties of ascitic fluids and peritoneal fluids from patients with ovarian tumors". Br. J. Cancer. 1991, 63, 102.

[39] Karasik A., Menczer J., Pariente C., Kanety H.: ·'Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer". Clin. Endocrinol. Metab., 1994, 7, 271.

[40] Shah N. G.,B hatavdekar J. M.,D octor S. S.,S uthar T. P., Balar D B.,D ave R. S.: "Circulating epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) in patients with epithelial ovarian carcinoma". Neoplasma, 1994, 41, 241.

[41] Bese T., Aksu F., Ahangari S., Erel T., idil M., Kosebay D. : "ileri evre epitelyal over kanserinde serum IGF-1 (Insliline bcnzeyen btiytime faktdrti-I) dtizeyleri: On calisma sonuclan". Jinekeoloji ve Obstetrik Dergisi, 1996, 10 (ek. 2), 89.

[42] Yu H., Berkel H.: "Insulin-like growth factors and cancer". J. La State Med. Soc.. 1999, 151, 218.

[43] Ben-Hur H., Gurevich P., Huszar M., Ben-Arie A., Berman V., Tedler Y. et al.: "Apoptosis related proteins in the epitheliam of human ovarian tumors: lmmunohistochemical and morphometric studies" Eur. J. Gynaecol. Oncol., 1999, 20, 249.

[44] Diebold J.. Baretton G.,F elchner M., Meier W.,D opfer K., Schidt M., Lohrs U.: "bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas". Am. J. Clin. Pathol., 1996, 105, 341.